Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHA-022121 oral prophylaxis dose-ranging study in hereditary angioedema
2023-505549-18-00Phase 2Completed
- Sponsor
- Pharvaris
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of deucrictibant in hereditary angioedema (HAE) (3 arms), sponsored by Pharvaris. Started Mar 2024; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2023-505549-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505549-18-00.